EGFR and non-small cell lung carcinoma: Moreover, the safety and activity of patritumab deruxtecan in patients with advanced EGFR-mutated NSCLC after failure of EGFR-TKI and platinum-based chemotherapy have been evaluated in a phase I clinical trial (NCT03260491).